How it works:
Lenvatinib is a multi-targeted tyrosine kinase inhibitor that blocks tumour angiogenesis and proliferation. It acts on VEGFR, FGFR, PDGFR, RET and KIT signalling pathways, reducing tumour growth and blood vessel formation.
Recommended for:
Patients with radioactive iodine-refractory differentiated thyroid cancer
Patients with hepatocellular carcinoma
Patients with renal cell carcinoma (in combination with other treatments)
Individuals eligible for targeted therapy
Differentiated thyroid carcinoma (DTC), resistant to radioactive iodine
Hepatocellular carcinoma
Advanced renal cell carcinoma (often combined with immune checkpoint inhibitors)
The tablet is taken once daily, with or without food. Dosage and treatment duration are determined by a qualified oncologist based on cancer type, patient condition, and tolerability. Dose adjustments may be required during treatment.
Hypersensitivity to lenvatinib or excipients
Pregnancy and breastfeeding
Uncontrolled hypertension
Decompensated heart failure
Recent gastrointestinal bleeding or perforation
High blood pressure
Diarrhoea, appetite loss, weight loss
Fatigue, headache
Joint and muscle pain
Hepatic and renal function impairment
Proteinuria
Skin rash
